Vitiligo therapy: restoring immune privilege?

Katia Boniface; Julien Seneschal; Alain Taïeb; Aksam Merched

doi:10.1111/exd.13128

Vitiligo therapy: restoring immune privilege?

Exp Dermatol. 2017 Jul;26(7):635-636. doi: 10.1111/exd.13128. Epub 2017 Jan 4.

Authors

Katia Boniface¹, Julien Seneschal^{1

2}, Alain Taïeb^{1

2}, Aksam Merched³

Affiliations

¹ INSERM U 1035, BMGIC, University of Bordeaux, Bordeaux, France.
² National Reference Centre for Rare Skin Disorders, Department of Dermatology and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France.
³ INSERM U1053, Bordeaux Research in Translational Oncology, University of Bordeaux, Bordeaux, France.

PMID: 27314920
DOI: 10.1111/exd.13128

Abstract

The therapeutic hypothesis proposed by Speeckaert and van Geel in this issue (1) is based on the dramatic effects of the new drugs targeting immune privilege checkpoints (PD1/PDL, CTLA4) in current advanced melanoma therapy as major inductors of vitiligo changes in the skin. Such striking clinical manifestations cannot be classified as mere side effects without considering possible consequences for spontaneously occurring vitiligo."

Keywords: immune privilege; melanoma; vitiligo.

Publication types

Comment

MeSH terms

B7-H1 Antigen / immunology
CTLA-4 Antigen / immunology
Genetic Predisposition to Disease
Genome-Wide Association Study
Humans
Hypopigmentation
Immune Privilege*
Immune System
Inflammation
Melanocytes / cytology
Melanoma / immunology
Melanoma / therapy*
Programmed Cell Death 1 Receptor / immunology
Risk
Signal Transduction
Skin
Skin Neoplasms / immunology
Skin Neoplasms / therapy*
Vitiligo / immunology*
Vitiligo / therapy*

Substances

B7-H1 Antigen
CD274 protein, human
CTLA-4 Antigen
CTLA4 protein, human
PDCD1 protein, human
Programmed Cell Death 1 Receptor